Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Dr. Zhengqing Li, an Experienced China Pharma Exec, Joins Ascletis

publication date: Mar 13, 2019

Dr. Zhengqing Li recently joined Ascletis, a Hangzhou company focused on therapeutic areas including anti-viral, cancer and fatty liver diseases, as Chief Medical Officer and President of R&D Greater China. Prior to Ascletis, Dr. Li worked at MSD China from 2011 to last month, where he served as Global Vice President and General Manager of the MSD R&D Center China. During his tenure, he built MSD China into a fully integrated development organization with more than 600 employees that led more than 20 product or new indication approvals in China. In an exclusive interview, Dr. Li spoke with ChinaBio® Today, discussing his path and what's next for Ascletis. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital